MatthewCFosterMD
Oncology • Chapel Hill, NCHematologic Oncology
Assistant Professor, Medicine, University of North Carolina at Chapel Hill School of Medicine
Dr. Foster is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
101 Manning Dr
Chapel Hill, NC 27514Phone+1 984-974-0000Fax+1 919-843-6949
Education & Training
University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2006 - 2009- University of North Carolina HospitalsResidency, Internal Medicine, 2002 - 2005
University of North Carolina at Chapel Hill School of MedicineClass of 2002
Certifications & Licensure
NC State Medical License 2005 - 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias Start of enrollment: 2010 Sep 01
- Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction Start of enrollment: 2012 Jun 28
- Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
- Join now to see all
Publications & Presentations
PubMed
- Cancer-related cognitive impairment in older adults with acute myeloid leukemia treated with hypomethylating agents and venetoclax chemotherapy: a longitudinal descrip...Ya-Ning Chan, Youngmin Cho, Rachel Hirschey, Aaron Piepmeier, Catherine M Bender
Supportive Care in Cancer. 2024-07-03 - 1 citationsComprehensive genomic profiling reveals molecular subsets of-mutated myeloid neoplasms.Steven M Johnson, James Haberberger, Jonathan Galeotti, Lori Ramkissoon, Catherine C Coombs
Leukemia & Lymphoma. 2024-02-01 - 7 citationsA study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.Sheng F Cai, Ying Huang, Jennie R Lance, Hsiaoyin Charlene Mao, Andrew J Dunbar
Blood Advances. 2024-01-23
Abstracts/Posters
- Oral Adherence in Adults with Acute Myeloid Leukemia: Results of a Mixed Methods StudyMatthew C Foster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) PatientsMatthew C Foster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AMLMatthew C Foster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Trials and Tribulations of Corrected QT Interval Monitoring in Oncology: Rationale for a Practice-Changing Standardized ApproachJuly 16th, 2019
Duke Researchers Discover How Leukemia Spreads to the BrainAugust 8th, 2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
